The costs of depression: Direct and indirect; treatment versus nontreatment

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 20, 1998, Pages 11-14

  Panzarino Jr , Peter J ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL PRACTICE; COMORBIDITY; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST CONTROL; DEPRESSION; FUNCTIONAL DISEASE; HEALTH CARE COST; HUMAN; MANAGED CARE; MEDICAL DECISION MAKING; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SOCIAL INTERACTION;

ANTIDEPRESSIVE AGENTS; COMORBIDITY; COST OF ILLNESS; DEPRESSIVE DISORDER; DIRECT SERVICE COSTS; DRUG COSTS; HEALTH CARE COSTS; HUMANS; MENTAL DISORDERS; PREVALENCE; PRIMARY HEALTH CARE; TREATMENT OUTCOME;

EID: 0032407611     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system: Epidemiologic Catchment Area prospective one-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50:85-94
2. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989; 262:914-919
3. Malzberg B. Mortality among patients with involution melancholia. Am J Psychiatry 1937;93:1231-1238
4. Odegard O. The excess mortality of the insane. Acta Psychiatr Scand 1952;27:353-367
5. Kessler LG, Cleary PD, Burke JD Jr. Psychiatric disorders in primary care: results of a follow-up study. Arch Gen Psychiatry 1985;42:583-587
6. Shapiro S, Skinner EA, Kessler LG, et al. Utilization of health and mental health services: three Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1984;41:971-978
7. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on six-month survival. JAMA 1993;270:1819-1825
8. Bentkover JD, Feighner JP. Cost analysis of paroxetine versus imipramine in major depression. Pharmaco-Economics 1995;8:223-232
9. Jonsson B, Bebbington PE. What price depression? the cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164:665-673
10. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-418
11. Bruce ML, Leaf PJ, Rozal GP, et al. Psychiatric status and nine-year mortality data in the New Haven Epidemiologic Catchment Area study. Am J Psychiatry 1994;151:716-721
12. Everson SA, Goldberg DE, Kaplan GA, et al. Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom Med 1996;58:113-121
13. Kroenke K, Mangelsdorff AD. Common symptoms in ambulatory care: incidence, evaluation, therapy and outcome. Am J Med 1989;86:262-266
14. Katon W, Von Korff M, Lin E, et al. Distressed high utilizers of medical care: DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry 1990;12:355-362
15. Simon GE. Psychiatric disorder and functional somatic symptoms as predictors of health care use. Psychiatric Medicine 1992;10:49-59
16. Rovner BW, German PS, Brant LJ, et al. Depression and mortality in nursing homes. JAMA 1991;265:993-996
17. Ahern DK, Gorkin L, Anderson JL, et al. Cardiac Arrhythmia Pilot Study (CAPS) investigators: biobchavioral variables and mortality of cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS). Am J Cardiol 1990;66: 59-62
18. Anda RF, Williamson DF, Jones D, et al. Depressed affect, hopelessness and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology 1993;4:285-294
19. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction and total mortality in a community sample. Circulation 1996;93: 1976-1980
20. Wells KB, Sturm R. Care for depression in a changing environment. Health Aff 1995;14:78-89
21. Rogers WH, Wells KB, Meredith LS, et al. Outcomes for adult outpatients with depression under prepaid or fee-for-service financing. Arch Gen Psychiatry 1993;50:517-525
22. Agency for Health Care Policy and Research. Clinical Practice Guideline, No. 5: Depression in Primary Care, vol 2, Treatment of Major Depression. AHCPR publication 93-0551. Rockville, Md: US Dept Health and Human Services; April 1993
23. Simon G, Wagner E, Von Korff M. Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs. J Clin Epidemiology 1995;48:363-373
24. Stewart A. Antidepressant pharmacotherapy: cost comparison of SSRIs and TCAs. Br J of Med Economics 1994;7:67-79
25. Le Pen C, Levy E, Ravily V, et al. The cost of treatment dropout in depression: a cost-benefit analysis of fluoxetine versus tricyclics. J Affect Disord 1994;31:1-18
26. Mauch RP Jr. Cost-effective treatment of depression. Am J Managed Care 1996;2:1269-1270
27. Sussman N, Castaneda R. The psychopharmacology of depression in the managed care setting. Am J Managed Care 1996;2:1249-1254
28. Thompson D, Buesching D, Gregor KJ, et al. Patterns of antidepressant use and their relation to costs of care. Am J Managed Care 1996;2: 1239-1246